Novozymes AS (NVZMY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Novozymes AS, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Novozymes AS (NVZMY) has returned -4.93% so far this year and 5.17% over the past 12 months. Over the last ten years, NVZMY has returned 4.54% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jul 13, 2007, NVZMY's average daily return is +0.03%, while the average monthly return is +0.44%. At this rate, your investment would double in approximately 13.2 years.

Historically, 56% of months were positive and 44% were negative. The best month was Jul 2010 with a return of +20.3%, while the worst month was Dec 2011 at -81.1%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NVZMY closed higher 49% of trading days. The best single day was Oct 17, 2008 with a return of +26.9%, while the worst single day was Dec 12, 2011 at -80.5%.

Novozymes AS has an annualized alpha of 1.36%, beta of 0.60, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since July 16, 2007.

• This stock participated in 95.02% of S&P 500 Index downside but only 48.86% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.60 may look defensive, but with R² of 0.10 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVZMY ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Novozymes AS (NVZMY) and compare them to a chosen benchmark (S&P 500 Index).

Novozymes AS provided a 2.73% dividend yield over the last twelve months, with an annual payout of $1.63 per share.

The table displays the monthly dividend distributions for Novozymes AS. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Novozymes AS. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novozymes AS was 86.29%, occurring on Aug 2, 2012. The portfolio has not yet recovered.

The current Novozymes AS drawdown is 59.08%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Novozymes AS over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Novozymes AS is priced in the market compared to other companies in the Specialty Chemicals industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.